INOVIO PHARMACEUTICALS, INC. (INO)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, INOVIO PHARMACEUTICALS, INC. reported revenue of $65.3K, down 70.0% from the prior year. The company ran a net loss, with a net margin of -130000.0%. It held $74.31M in total assets against $50.21M in total liabilities.
Key ratios (FY2025)
-132871.3%
Operating margin
-130000.0%
Net margin
-352.5%
Return on equity
-70.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3K | $217.8K | $832.0K | $10.26M | $1.77M | $7.41M | $4.11M | $30.48M | $42.22M | $35.37M |
| Operating Income | -$86.82M | -$112.40M | -$143.94M | -$267.57M | -$301.22M | -$124.08M | -$111.11M | -$94.09M | -$83.64M | -$76.24M |
| Net Income | -$84.95M | -$107.25M | -$135.12M | -$279.82M | -$303.66M | -$166.41M | -$119.36M | -$96.97M | -$88.21M | -$73.74M |
| EPS (Diluted) | $-1.81 | $-3.95 | $-6.09 | $-14.07 | $-17.45 | $-1.07 | $-1.21 | $-1.05 | $-1.09 | $-1.01 |
| Total Assets | $74.31M | $113.20M | $170.95M | $348.53M | $495.94M | $539.77M | $143.95M | $131.11M | $187.24M | $173.71M |
| Total Liabilities | $50.21M | $44.69M | $53.60M | $126.17M | $96.27M | $78.63M | $138.55M | $44.08M | $44.75M | $50.33M |
| Shareholders' Equity | $24.10M | $68.50M | $117.35M | $222.36M | $399.67M | $461.14M | $3.44M | $86.94M | $142.39M | $123.28M |
| Cash & Equivalents | $44.27M | $65.81M | $14.31M | $46.33M | $71.14M | $250.73M | $22.20M | $23.69M | $23.79M | $19.14M |
| Operating Cash Flow | -$88.63M | -$104.08M | -$124.37M | -$216.22M | -$215.71M | -$177.98M | -$97.85M | -$73.55M | -$63.21M | -$62.56M |
| Capital Expenditures | $285.7K | $487.8K | $320.9K | $969.2K | $1.23M | $1.52M | $987.9K | $2.09M | $10.29M | $2.74M |
| Shares Outstanding | 69.00M | 36.10M | 22.79M | 21.09M | 217.38M | 186.85M | 101.36M | 97.23M | 90.36M | 74.06M |